Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma

Pearl E. Grimes, Jag Bhawan, Ian L. Guevara, Luz E. Colón, Lori A. Johnson, Ronald W. Gottschalk, Amit G. Pandya

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Melasma is often recalcitrant to treatment. Triple combination (TC) cream is an effective and approved treatment for melasma. Objective: We sought to determine the efficacy and safety of continuous therapy followed by a maintenance treatment regimen during a period of 24 weeks with a TC cream containing hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%. Methods: Seventy patients with melasma were treated with a TC cream daily for 12 weeks, after which, if clear or almost clear, they applied the cream twice per week for 12 more weeks. For patients who were not clear or almost clear after 12 weeks, daily treatment was continued. Results: In all, 25 patients completing the study per protocol were treated daily for 24 weeks (cohort A); 6 patients were treated daily for 12 weeks followed by 12 weeks of maintenance therapy (cohort B); and 21 patients were treated daily for 12 weeks, relapsed during the maintenance phase, and returned to daily dosing (cohort C). Pigmentation was significantly reduced at weeks 12 and 24 and global melasma severity improved at week 24 in cohorts A and C compared with baseline. Adverse events occurred in 53% of patients and were primarily mild in severity. Limitations: This was an open-label trial. Conclusion: About half of patients treated with a TC cream for melasma were able to begin maintenance therapy twice per week after 12 weeks; however, relapses occurred in most of these patients, requiring resumption of daily therapy. The cream is safe in the treatment of moderate to severe melasma for up to 24 weeks when used intermittently or continuously. Significant reductions in melasma severity scores were seen at weeks 12 and 24 when compared with baseline scores in all evaluable study groups.

Original languageEnglish (US)
Pages (from-to)962-967
Number of pages6
JournalJournal of the American Academy of Dermatology
Volume62
Issue number6
DOIs
StatePublished - Jun 2010

Fingerprint

Melanosis
Therapeutics
Fluocinolone Acetonide
Pigmentation
Tretinoin
Maintenance
Safety
Recurrence

Keywords

  • hydroquinone
  • melasma
  • pigmentation
  • tretinoin

ASJC Scopus subject areas

  • Dermatology

Cite this

Grimes, P. E., Bhawan, J., Guevara, I. L., Colón, L. E., Johnson, L. A., Gottschalk, R. W., & Pandya, A. G. (2010). Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma. Journal of the American Academy of Dermatology, 62(6), 962-967. https://doi.org/10.1016/j.jaad.2009.06.067

Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma. / Grimes, Pearl E.; Bhawan, Jag; Guevara, Ian L.; Colón, Luz E.; Johnson, Lori A.; Gottschalk, Ronald W.; Pandya, Amit G.

In: Journal of the American Academy of Dermatology, Vol. 62, No. 6, 06.2010, p. 962-967.

Research output: Contribution to journalArticle

Grimes, PE, Bhawan, J, Guevara, IL, Colón, LE, Johnson, LA, Gottschalk, RW & Pandya, AG 2010, 'Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma', Journal of the American Academy of Dermatology, vol. 62, no. 6, pp. 962-967. https://doi.org/10.1016/j.jaad.2009.06.067
Grimes, Pearl E. ; Bhawan, Jag ; Guevara, Ian L. ; Colón, Luz E. ; Johnson, Lori A. ; Gottschalk, Ronald W. ; Pandya, Amit G. / Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma. In: Journal of the American Academy of Dermatology. 2010 ; Vol. 62, No. 6. pp. 962-967.
@article{177d793e725143bebf61ac583bc7087f,
title = "Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma",
abstract = "Background: Melasma is often recalcitrant to treatment. Triple combination (TC) cream is an effective and approved treatment for melasma. Objective: We sought to determine the efficacy and safety of continuous therapy followed by a maintenance treatment regimen during a period of 24 weeks with a TC cream containing hydroquinone 4{\%}, tretinoin 0.05{\%}, and fluocinolone acetonide 0.01{\%}. Methods: Seventy patients with melasma were treated with a TC cream daily for 12 weeks, after which, if clear or almost clear, they applied the cream twice per week for 12 more weeks. For patients who were not clear or almost clear after 12 weeks, daily treatment was continued. Results: In all, 25 patients completing the study per protocol were treated daily for 24 weeks (cohort A); 6 patients were treated daily for 12 weeks followed by 12 weeks of maintenance therapy (cohort B); and 21 patients were treated daily for 12 weeks, relapsed during the maintenance phase, and returned to daily dosing (cohort C). Pigmentation was significantly reduced at weeks 12 and 24 and global melasma severity improved at week 24 in cohorts A and C compared with baseline. Adverse events occurred in 53{\%} of patients and were primarily mild in severity. Limitations: This was an open-label trial. Conclusion: About half of patients treated with a TC cream for melasma were able to begin maintenance therapy twice per week after 12 weeks; however, relapses occurred in most of these patients, requiring resumption of daily therapy. The cream is safe in the treatment of moderate to severe melasma for up to 24 weeks when used intermittently or continuously. Significant reductions in melasma severity scores were seen at weeks 12 and 24 when compared with baseline scores in all evaluable study groups.",
keywords = "hydroquinone, melasma, pigmentation, tretinoin",
author = "Grimes, {Pearl E.} and Jag Bhawan and Guevara, {Ian L.} and Col{\'o}n, {Luz E.} and Johnson, {Lori A.} and Gottschalk, {Ronald W.} and Pandya, {Amit G.}",
year = "2010",
month = "6",
doi = "10.1016/j.jaad.2009.06.067",
language = "English (US)",
volume = "62",
pages = "962--967",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma

AU - Grimes, Pearl E.

AU - Bhawan, Jag

AU - Guevara, Ian L.

AU - Colón, Luz E.

AU - Johnson, Lori A.

AU - Gottschalk, Ronald W.

AU - Pandya, Amit G.

PY - 2010/6

Y1 - 2010/6

N2 - Background: Melasma is often recalcitrant to treatment. Triple combination (TC) cream is an effective and approved treatment for melasma. Objective: We sought to determine the efficacy and safety of continuous therapy followed by a maintenance treatment regimen during a period of 24 weeks with a TC cream containing hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%. Methods: Seventy patients with melasma were treated with a TC cream daily for 12 weeks, after which, if clear or almost clear, they applied the cream twice per week for 12 more weeks. For patients who were not clear or almost clear after 12 weeks, daily treatment was continued. Results: In all, 25 patients completing the study per protocol were treated daily for 24 weeks (cohort A); 6 patients were treated daily for 12 weeks followed by 12 weeks of maintenance therapy (cohort B); and 21 patients were treated daily for 12 weeks, relapsed during the maintenance phase, and returned to daily dosing (cohort C). Pigmentation was significantly reduced at weeks 12 and 24 and global melasma severity improved at week 24 in cohorts A and C compared with baseline. Adverse events occurred in 53% of patients and were primarily mild in severity. Limitations: This was an open-label trial. Conclusion: About half of patients treated with a TC cream for melasma were able to begin maintenance therapy twice per week after 12 weeks; however, relapses occurred in most of these patients, requiring resumption of daily therapy. The cream is safe in the treatment of moderate to severe melasma for up to 24 weeks when used intermittently or continuously. Significant reductions in melasma severity scores were seen at weeks 12 and 24 when compared with baseline scores in all evaluable study groups.

AB - Background: Melasma is often recalcitrant to treatment. Triple combination (TC) cream is an effective and approved treatment for melasma. Objective: We sought to determine the efficacy and safety of continuous therapy followed by a maintenance treatment regimen during a period of 24 weeks with a TC cream containing hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%. Methods: Seventy patients with melasma were treated with a TC cream daily for 12 weeks, after which, if clear or almost clear, they applied the cream twice per week for 12 more weeks. For patients who were not clear or almost clear after 12 weeks, daily treatment was continued. Results: In all, 25 patients completing the study per protocol were treated daily for 24 weeks (cohort A); 6 patients were treated daily for 12 weeks followed by 12 weeks of maintenance therapy (cohort B); and 21 patients were treated daily for 12 weeks, relapsed during the maintenance phase, and returned to daily dosing (cohort C). Pigmentation was significantly reduced at weeks 12 and 24 and global melasma severity improved at week 24 in cohorts A and C compared with baseline. Adverse events occurred in 53% of patients and were primarily mild in severity. Limitations: This was an open-label trial. Conclusion: About half of patients treated with a TC cream for melasma were able to begin maintenance therapy twice per week after 12 weeks; however, relapses occurred in most of these patients, requiring resumption of daily therapy. The cream is safe in the treatment of moderate to severe melasma for up to 24 weeks when used intermittently or continuously. Significant reductions in melasma severity scores were seen at weeks 12 and 24 when compared with baseline scores in all evaluable study groups.

KW - hydroquinone

KW - melasma

KW - pigmentation

KW - tretinoin

UR - http://www.scopus.com/inward/record.url?scp=77951937570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951937570&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2009.06.067

DO - 10.1016/j.jaad.2009.06.067

M3 - Article

C2 - 20398959

AN - SCOPUS:77951937570

VL - 62

SP - 962

EP - 967

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 6

ER -